Omeros (OMER) Cash from Investing Activities (2010 - 2026)
Omeros (OMER) posted Cash from Investing Activities of $28.7 million for Q1 2026, down 74.24% sequentially from $111.5 million in Q4 2025, and down 25.45% YoY from $38.5 million in Q1 2025.
Analysis
Omeros (OMER) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Omeros has reported Cash from Investing Activities for 17 years, with the latest figure at $28.7 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 25.45% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.7 million (down 15.31% YoY) and the FY2025 annual result came in at $164.5 million, up 100.11% from the prior year.
- Cash from Investing Activities slipped to $28.7 million in Q1 2026 per OMER's latest filing, from $111.5 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $116.2 million in Q4 2023 and troughed at -$181.3 million in Q1 2023.
- A 5-year average of $10.3 million and a median of $33.0 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 332.87% in 2022, then jumped 219.12% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$108.5 million in 2022, then surged by 207.15% to $116.2 million in 2023, then plunged by 69.93% to $35.0 million in 2024, then surged by 219.12% to $111.5 million in 2025, then sank by 74.24% to $28.7 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $28.7 million, $111.5 million, and -$6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 3.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.40 Mn |
| Mar 31, 2026 | 28.73 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Mar 31, 2025 | 38.54 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Sep 30, 2024 | 36.04 Mn |
| Jun 30, 2024 | 73.15 Mn |
| Mar 31, 2024 | -61.93 Mn |
| Dec 31, 2023 | 116.24 Mn |
| Sep 30, 2023 | 57.17 Mn |
| Jun 30, 2023 | 35.38 Mn |
| Mar 31, 2023 | -181.33 Mn |
| Dec 31, 2022 | -108.49 Mn |
| Sep 30, 2022 | 33.00 Mn |
| Jun 30, 2022 | 24.74 Mn |
| Mar 31, 2022 | -76.81 Mn |
| Dec 31, 2021 | 112.42 Mn |
| Sep 30, 2021 | 17.90 Mn |